Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
57 hedge funds and large institutions have $283M invested in Audentes Therapeutics, Inc in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
16% more funds holding
Funds holding: 49 → 57 (+8)
4% more capital invested
Capital invested by funds: $272M → $283M (+$10.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.61M |
| 2 |
Millennium Management
New York
|
+$1.52M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$833K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$557K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$499K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.02M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.67M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$1.45M |
| 4 |
OA
Omega Advisors
New York
|
-$816K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$708K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $23K | +$23.2K | +1,344 | New |
|
52
Legal & General Group
London,
United Kingdom
| $20K | +$18.7K | +1,084 | New |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $8K | +$725 | +42 | +11% |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | +$2.94K | +170 | +170% |
|
55
BNP Paribas Financial Markets
Paris,
France
| $2.34K | -$1.35K | -78 | -38% |
|
56
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2K | +$1.42K | +82 | New |
|
|
SFM
57
Sphera Funds Management
Tel Aviv,
Israel
| – | -$2.67M | -150,000 | Closed |
|
|
OA
58
Omega Advisors
New York
| – | -$816K | -45,800 | Closed |
|
|
LCM
59
Laurion Capital Management
New York
| – | -$267K | -15,000 | Closed |
|
60
UBS Group
Zurich,
Switzerland
| – | -$25K | -1,394 | Closed |
|
61
Citigroup
New York
| – | -$8.03K | -465 | -99% |
|
|
CCA
62
Catalyst Capital Advisors
Huntington,
New York
| – | -$4K | -230 | Closed |
|
BOLD Hedge Fund Activity: Q4 2016 in Review
57 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q4 2016, worth a combined $283M — up 4% from $272M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BOLD positions and 5 closed out — a net gain of 8 holders — while 13 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $5.61M. The largest seller was RA Capital Management, cutting an estimated $3.02M.
- 57 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q4 2016, up from 49 in Q3 2016.
- Funds reported $283M of Audentes Therapeutics, Inc stock for Q4 2016, up 4% quarter-over-quarter.
- 13 funds opened new Audentes Therapeutics, Inc positions in Q4 2016 and 5 closed out, a net change of +8 holders.
- The largest Audentes Therapeutics, Inc buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $5.61M added.
- The largest Audentes Therapeutics, Inc seller in Q4 2016 was RA Capital Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q4 2016.